Evidence map›Paper›PMID 40232552›Full record

ArticleJournal of hematopathology2025

Day + 100 bone marrow megakaryocyte count predicts transplant outcome in patients with high-risk myelodysplastic syndrome and acute leukemia.

Zeynep Arzu Yegin, Şeyma Yıldız, Emine Merve Savaş, Ali Şeker, Pınar Uyar Göçün, Zübeyde Nur Özkurt, Nalan Akyürek, Münci Yağcı

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of hematopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zeynep Arzu YeginGazi University, Ankara, Turkey. zeyneparzuyegin@gmail.com.
Şeyma YıldızGazi University, Ankara, Turkey.
Emine Merve SavaşGazi University, Ankara, Turkey.
Ali ŞekerGazi University, Ankara, Turkey.
Pınar Uyar GöçünGazi University, Ankara, Turkey.
Zübeyde Nur ÖzkurtGazi University, Ankara, Turkey.
Nalan AkyürekGazi University, Ankara, Turkey.
Münci YağcıGazi University, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Megakaryocytes (MKs), the precursor cells of platelets, have essential roles in a variety of pathophysiological processes in the bone marrow (BM) niche. Megakaryocytes maintain hematopoietic stem cell microenvironment through inflammatory and immunological responses. The primary objective of this research was to investigate the clinical impact of BM-MK counts in high-risk myelodysplastic syndrome and acute leukemia patients who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT). Three hundred and forty-six patients (median age, 42 (15-71) years; male/female, 207/139) participated in the study. Based on the BM-MK counts on day + 100 of alloHSCT, the study population was classified into normal/high-MK

Indexed as

Bone MarrowHematopoietic Stem Cell TransplantationLeukemiaMegakaryocytesMyelodysplastic SyndromesAdolescentAdultAgedCell CountFemaleHumansMaleMiddle AgedPrognosisTreatment OutcomeYoung AdultAcute leukemiaAllogeneic hematopoietic stem cell transplantationMegakaryocyteMyelodysplastic syndromePlatelet

Identifiers

PMID40232552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.